Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals, a developer of innovative drug candidates for the treatment of autoimmune and central nervous system diseases, has announced the issuance of US patent containing claims covering the use of thiomolybdates such as oral tiomolibdate diammonium for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
According to the company, oral tiomolibdate diammonium’s specificity and unique mechanism of action for rapidly lowering toxic ‘free’ copper levels may position the drug as the first available therapeutic agent capable of correcting the serum and CNS ‘free’ copper dyshomeostasis that may represent an important fundamental cause of Alzheimer’s disease (AD).
Oral tiomolibdate diammonium is currently being studied in preclinical models for the treatment of AD.
Nicholas Stergis, CEO of Adeona, said: “We are pleased to have added this issued US issued patent to our portfolio of anti-copper therapies. As we continue to seek partnerships with industry and non-profit foundations, we believe we may realize value from this set of intellectual property.”